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Summary
Background Diagnosis and remission status at the time of allogeneic haematopoietic stem-cell transplantation (HSCT) 
are the principal determinants of overall survival following transplantation. We sought to develop a contemporary 
disease-risk stratification system (DRSS) that accounts for heterogeneous transplantation indications.
Methods In this retrospective cohort study we included 55 histology and remission status combinations across 
haematological malignancies, including acute leukaemia, lymphoma, multiple myeloma, and myeloproliferative and 
myelodysplastic disorders. A total of 47 265 adult patients (aged ≥18 years) who received an allogeneic HSCT between 
Jan 1, 2012, and Dec 31, 2016, and were reported to the European Society for Blood and Marrow Transplantation 
registry were included. We divided EBMT patients into derivation (n=25 534), tuning (n=18 365), and geographical 
validation (n=3366) cohorts. Disease combinations were ranked in a multivariable Cox regression for overall survival 
in the derivation cohort, cutoff for risk groups were evaluated for the tuning cohort, and the selected system was 
tested on the geographical validation cohort. An independent single-centre US cohort of 660 patients transplanted 
between Jan 1, 2010, and Dec 31, 2015 was used to externally validate the results.
Findings The DRSS model stratified patients in the derivation cohort (median follow-up was 2·1 years [IQR 1·0–3·2]) 
into five risk groups with increasing mortality risk: low risk (reference group), intermediate-1 (hazard ratio for 
overall survival 1·26 [95% CI 1·17–1·36], p<0·0001), intermediate-2 (1·53 [1·42–1·66], p<0·0001), high 
(2·03 [1·86–2·22], p<0·0001), and very high (2·87 [2·63–3·13], p<0·0001). DRSS levels were also associated with a 
stepwise increase in risk across the tuning and geographical validation cohort. In the external validation cohort 
(median follow-up was 5·7 years [IQR 4·5–7·1]), the DRSS scheme separated patients into 4 risk groups associated 
with increasing risk of mortality: intermediate-2 risk (hazard ratio [HR] 1·34 [95% CI 1·04–1·74], p=0·025), high 
risk (HR 2·03 [95% CI 1·39–2·95], p=0·00023) and very-high risk (HR 2·26 [95% CI 1·62–3·15], p<0·0001) patients 
compared with the low risk and intermediate-1 risk group (reference group). Across all cohorts, between 64% and 
65% of patients were categorised as having intermediate-risk disease by a previous prognostic system (ie, the disease-
risk index [DRI]). The DRSS reclassified these intermediate-risk DRI patients, with 855 (6%) low risk, 7111 (51%) 
intermediate-1 risk, 5700 (41%) intermediate-2 risk, and 375 (3%) high risk or very high risk of 14 041 patients in a 
subanalysis combining the tuning and internal geographic validation cohorts. The DRI projected 2-year overall 
survival was 62·1% (95% CI 61·2–62·9) for these 14 041 patients, while the DRSS reclassified them into finer 
prognostic groups with overall survival ranging from 45·7% (37·4–54·0; very high risk patients) to 73·1% 
(70·1–76·2; low risk patients).
Interpretation The DRSS is a novel risk stratification tool including disease features related to histology, genetic 
profile, and treatment response. The model should serve as a benchmark for future studies. This system facilitates 
the interpretation and analysis of studies with heterogeneous cohorts, promoting trial-design with more inclusive 
populations.
Funding The Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University.
Copyright © 2021 Elsevier Ltd. All rights reserved
Introduction 
Relapse remains a stubborn barrier to successful allo­
geneic haematopoietic stem­cell transplantation (HSCT), 
occurring in nearly a third of transplantations.1 Diagnosis 
and remission status at the time of transplantation are 
among the strongest predictors of relapse and death.1–4 
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Accounting for these factors is imperative when 
contemplating transplantation, designing a clinical trial, 
or analysing outcomes.
To standardise the process of pre­transplantation risk 
assessment, prognostic systems have categorised risk 
on the basis of the combination of disease and remission 
status.2,3,5–7 The disease­risk index (DRI)2,3 has proven 
valuable and is considered the standard for prog­
nostication in cohorts with heterogeneous diagnoses.8,9 
Nevertheless, the DRI was developed on patients who 
were transplanted over a decade ago and assigns 
the bulk of recipients to the intermediate­disease­risk 
category.2,3 Ideally, a prognostic model would reflect 
more recent practice and provide finer, actionable 
categories. Therefore, we sought to develop and validate 
a more contemporary disease­risk stratification system 
(DRSS) for patients with haematological malig nan­
cies under going allogeneic HSCT. Such a system 
could promote the design of non­disease­specific trials 
by accounting for the population’s heterogeneity, 
increasing power and generalisability of results. 
Further more, the DRSS could contribute to the analysis 
and interpretation of prospective and retrospective 
studies.
Methods 
Study design and data sources 
The European Society for Blood and Marrow 
Transplantation (EBMT) maintains an audited registry of 
HSCT done by member­institutions. Over 600 par tic­
ipating centres, located mainly in Europe, submit 
anonymised data following patient informed consent. 
For model development and internal validation, we 
included 47 265 adult allogeneic HSCT recipients (aged 
≥18 years) with haematological malignancies reported to 
the registry between Jan 1, 2012, and Dec 31, 2016. For 
external validation, we included 660 patients transplanted 
at the Memorial Sloan Kettering Cancer Center (MSKCC) 
between Jan 1, 2010, and Dec 31, 2015. Patients receiving 
cord blood grafts or cells from HLA­mismatched related 
donors were not included in the MSKCC cohort.
We divided EBMT patients into derivation (n=25 534), 
tuning (n=18 365), and geographical validation (n=3366) 
cohorts.10 Briefly, combinations of disease and remission 
status were studied and ranked according to mortality 
risk on the derivation cohort, which included patients 
transplanted between Jan 1, 2014, and Dec 31, 2016. As 
there is no so­called ground truth for defining risk 
groups, we generated several potential risk groups 
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Research in context
Evidence before this study
We searched PubMed for the terms (“disease risk”) OR 
(“disease status”) AND (“allogeneic stem-cell transplantation”) 
in reports published in any language from database inception 
up to Aug 9, 2020, to identify relevant published clinical data. 
We found several prognostic systems that incorporated 
disease and disease status to stratify patients by risk of overall 
mortality. Up until August, 2020, the revised Disease Risk 
Index (DRI) was the most comprehensive and widely used. 
The DRI has been successfully applied in retrospective and 
prospective studies. However, the DRI was developed on 
transplants done between the years 2008 and 2010 and does 
not reflect subsequent changes in patients and disease 
profiles. In addition, the DRI does not capture informative 
features in acute myeloid leukaemia, such as disease origin, 
molecular features (eg, FLT3 and NPM1 mutations), and 
specific cytogenetic aberrations that are known to affect 
outcome. Finally, across studies implementing the DRI, 
approximately 70% of patients were classified as being 
intermediate risk, limiting the system’s ability to discriminate 
between patients who are classified as truly high and patients 
who are classified as being low risk who could benefit from 
targeted interventions.
Added value of this study
In this large international registry-based study, we developed 
and internally and externally validated a disease-risk 
stratification system for overall survival, grouping 
55 combinations of disease and disease status into five risk 
tiers. An increasing tendency to relapse drives the incremental 
risk of mortality between tiers. To our knowledge, this is the 
first global prognostic system which subdivides acute myeloid 
leukaemia, the leading allogeneic transplant indication, 
by ontology (ie, de-novo vs secondary), cytogenetics, and 
FLT3 and NPM1 mutational status. The new system reclassifies 
patients previously considered to have intermediate-risk 
disease by the DRI into finer, potentially actionable, prognostic 
categories. Finally, to our knowledge, our study is the most 
comprehensive and most recent prognostic system for patients 
with haematological malignancies undergoing allogeneic 
transplantation. It was developed, optimised, and validated on 
47 925 patients, highlighting its robustness and 
generalisability.
Implications of all the available evidence
Our system reflects an up-to-date approach for risk stratification 
in patients with haematological malignancies undergoing 
allogeneic haematopoietic stem­cell transplantation. 
It facilitates the interpretation and analysis of prospective and 
retrospective studies with heterogeneous cohorts, promoting 
the design of non-disease-specific trials with broader, more 
inclusive populations. The system should also serve the medical 
community as a benchmark for transplantation outcomes in the 
coming years. Our approach lays the foundation for further 
iterations of this prognostic system, which will incorporate more 
detailed molecular information and data for measurable residual 
disease, both of which are increasingly being captured in 
transplantation registries.
For more on EBMT centres see 
https://www.ebmt.org/
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schemes on the derivation cohort and evaluated them on 
the tuning cohort, which included EBMT patients 
transplanted between Jan 1, 2012, and Dec 31, 2014. The 
selected scheme was then tested on the internal 
geographical validation and external validation cohorts, 
which were held throughout the training and tuning 
process. The internal geographical validation cohort 
comprised patients transplanted between Jan 1, 2014, and 
Dec 31, 2016, in Italian centres reporting to the EBMT 
and the external validation cohort was a cohort 
transplanted at MSKCC between Jan 1, 2010, and 
Dec 31, 2015. A schematic overview of the analytic plan is 
provided in the appendix (p 16).
Donor types and conditioning intensities were defined 
as previously described,1 following the EBMT working 
definitions. Briefly, 15 haematological malignancies were 
considered and further stratified by disease status at the 
time of transplantation. Additional genetic markers were 
studied for acute myeloid leukaemia, acute lymphoblastic 
leukaemia, and myelodysplastic syndrome. Acute myeloid 
leukaemia was first classified as de­novo or secondary on 
the basis of standard criteria.11,12 Cytogenetic risk definition 
in acute myeloid leukaemia was based on the European 
Leukemia Net definitions (appendix p 2),13 and patients in 
the intermediate­risk cytogenetic with de­novo acute 
myeloid leukaemia group were stratified by FLT3­ITD 
(FMS­like tyrosine kinase­3 internal tandem duplication) 
and NPM1 (nucleophosmin­1) mutation status. Myelo­
dysplastic syndrome was considered to have adverse 
cytogenetic risk features in patients with complex karyo­
type (≥3 chromosomal abnormalities) or the deletion or 
monosomy of chromosome 7.2 For acute lymphoblastic 
leukaemia, categorisation by the Philadelphia chromosome 
(Ph; t(9;22)(q34;q11) and BCR-ABL1) and t(4;11) and 
KMT2A-AFF1 were evaluated. As transplantation studies 
often have high rates of missing cytogenetic information, 
we kept missing cytogenetics in acute myeloid leukaemia, 
myelodysplastic syndrome, and acute lymphoblastic 
leukaemia as separate levels.
The Acute Leukemia Working Party, the EBMT 
Scientific Council, and MSKCC’s Institutional Review 
Board approved this study in accordance with the 
Declaration of Helsinki.
Outcomes 
The studied outcome was overall survival, measured 
from the time of stem­cell infusion to censoring or death 
from any cause. Relapse and non­relapse mortality were 
also assessed as competing events.
Statistical analysis 
In the first stage, disease and disease status pairs were 
constructed following the example outlined in the DRI.2,3 
New subcategories of clinical interest were added when 
sub­histologies had distinct survival outcome (p<0·05), as 
assessed by hazard ratio (HR) adjusted for recipient age, 
Karnofsky performance status, conditioning intensity, 
donor and cell type, donor and recipient sex mismatch, 
and cytomegalovirus serostatus pair with a random effect 
for centre in the derivation set. These changes included 
the division of acute myeloid leukaemia into de­novo and 
secondary acute myeloid leukaemia (as the de­novo acute 
myeloid leukaemia category was associated with better 
overall survival), separation of de­novo acute myeloid 
leukaemia into patients’ first complete remission and 
subsequent complete remission, stratification of de­novo 
acute myeloid leukaemia in patients’ first complete 
remission with intermediate cytogenetics based on 
FLT3­ITD and NPM1 status (to FLT3­ITD+ and NPM1WT vs 
all other combinations), stratification of de­novo acute 
myeloid leukaemia in patients’ subsequent complete 
remission based on adverse cytogenetics and FLT3­ITD 
status, stratification of secondary acute myeloid leukaemia 
in patients’ complete remission on the basis of adverse 
cytogenetics, and stratification of acute lympho blastic 
leukaemia in patients’ first complete remission based on 
t(9;22) status (appendix p 17). We explored and rejected 
the inclusion of t(4;11) in acute lymphoblastic leukaemia 
in patients’ first complete remission, as we did not find 
an association with differential survival (HR 1·32 [95% CI 
0·83–2·10]; p=0·24). Within acute myeloid leukaemia, 
myelodysplastic syndrome, and acute lympho blastic 
leukaemia in patients’ first complete remission, patients 
with unknown cytogenetics were categorised separately. 
Finally, we added biphenotypic acute leukaemia in 
patients’ complete remission and the myelodysplastic or 
myeloproliferative neoplasm overlap syndrome (myelo­
dysplastic syndrome and myelopro liferative neoplasm) as 
new diagnoses.
We constructed a mixed­effects multivariable Cox 
regression model for overall survival using the derivation 
set, with disease­disease status pair adjusted for recipient 
age, Karnofsky performance status, conditioning intensity, 
donor and cell type, donor and recipient sex mismatch, 
and cytomegalovirus serostatus pair with a random effect 
for centre. The β­coefficients of the disease and status 
pairs were ranked. To create a risk stratification system 
that would be easily applied, we sought β­coefficients 
cutoff points that would produce groups comprising 
between 10% and 40% of patients and incrementally 
predictive of mortality. We generated several different sets 
of cutoff points over the derivation cohort, which were 
selected by serially searching for optimal cutoff points 
using the maximally selected log­rank statistic;14 a method 
typically applied for identifying potential cutoff points in 
continuous covariates. Grouping schemes fitting our 
initial criteria were evaluated on the tuning cohort. The one 
scheme that resulted in clinically rational, homogeneous 
groups was then studied using a multi variable Cox 
regression model, adjusting for the same covariates as 
described for the disease­disease status pairs in this section 
(aside from centre effect on the single­centre validation 
cohort), on two datasets—the internal geographical 
validation and external validation cohorts (appendix p 16).
See Online for appendix
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Overall survival was calculated using the Kaplan­Meier 
method and compared by the log­rank statistic. All 
p values were two­sided and values less than 0·05 were 
considered significant without adjustment for multiple 
testing. Discrimination of the new system was compared 
with the revised DRI3 using time­dependent area under 
the receiver operating characteristic curve (AUC) 
statistic.15 Analyses were done using SPSS (version 25.0) 
and R (v.3.5.3).
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results 
Out of 54 076 patients in the EBMT registry, patients with 
missing overall survival status (n=528) or donor relation­
ship (n=941) or with insufficient information to establish 
diagnosis and disease status (n=4727) were excluded 
(figure 1). An additional 522 patients were dismissed 
because of disease­specific missing infor mation and 
93 because of the rarity of patients (sample size <50) in 
that diagnosis or status category (ie, Burkitt lymphoma 
and relapsed biphenotypic leukaemia). The final study 
population comprised of 47 265 patients. The median age 
of patients in the derivation cohort was 53 years 
(IQR 41–62; table 1). Acute myeloid leukaemia was the 
primary indication for transplantation, accounting for 
11 881 (47%) of 25 534 patients, followed by acute lympho­
blastic leukaemia (3474 patients; 13·6%), and myelo dys­
plastic syndrome (2977 patients; 11·7%).
Bone marrow grafts (occurring in 1128 [33·5%]), 
haploidentical donors (occurring in 897 [26·6%]), and 
myeloablative conditioning (occurring in 2494 [74·1%]) 
were more prevalent in the geographical­validation cohort 
(n=3366 patients) compared with the derivation cohort 
(n=25 534; 2126 [8·3%] for bone marrow grafts, 
1762 [6·9%] for haploidentical donors, and 12 476 [48·9%] 
for myeloablative conditioning). Median follow­up and 
com plete ness of follow­up16 at 2 years was 2·1 years 
(IQR 1·0–3·2) and 72·7% for the derivation cohort, 
4·6 years (1·9–5·6) and 83·8% for the tuning cohort, and 
3·0 years (2·3–3·9) and 94·8% for the geographical 
validation cohort.
On the derivation set, 55 possible disease and disease 
status­based combinations were studied in a multiv­
ariable Cox model. De­novo acute myeloid leukaemia in 
patients’ first complete remission with intermediate­risk 
cyto genetics and without the FLT3­ITD+ and NPM1WT 
muta tions was selected as the reference. The 
proportional increase of the adjusted hazard, relative to 
this reference, is shown in figure 2 (appendix p 3). To 
generate a prognostic scheme, which we refer to as the 
Figure 1: Study profile
The European Society for Blood and Marrow Transplantation cohort was split into derivation, tuning, and geographical validation cohorts. A cohort from Memorial Sloan Kettering Cancer Center 
served for external validation. HSCT=haematopoietic stem-cell transplantation.
54 076 registry patients treated between 2012 and
2016 for haematological malignancies with
first allogeneic HSCT
47 880 patients remaining 
47 265 included in the analysis
25 534 patients included in the derivation set
(2014–16, excluding Italian centres)
18 365 patients included in the tuning set
(2012–13, all centres)
3366 patients included in the geographical
validation set (2014–16, Italian centres)
660 patients included in the external
validation set (2010–15, Memorial Sloan
Kettering Cancer Center)
6196 not included
528 missing survival data
941 donor or patient relationship unknown, or combination
4727 unable to assign disease or status category
615 patients excluded 
93 excluded due to inadequate number of cases in disease or status category
(ie, Burkitt lymphoma and advanced biphenotypic leukaemia)
107 patients diagnosed with de novo acute myeloid leukaemia who were missing
remission status classification
415 patients missing excess blast status in myelodysplastic syndrome
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DRSS, disease and disease­status pairs were grouped by 
β­coefficient and thresholds were selected as described 
in the statistical analysis section in the Methods section. 
Several possible risk grouping schemes were generated 
on the derivation cohort and evaluated on the tuning 
cohort. Based on the criteria described in the Methods, 
the selected 5 levels scheme (ie, low risk, intermediate­1 
risk, intermediate­2 risk, high risk, and very­high risk 
groups) classified 3298 (13%) of the total 25 534 patients 
in the derivation cohort as low­risk, 9528 (37%) patients 
in the derivation cohort as intermediate­1 risk, 7072 (28%) 
patients in the derivation cohort as intermediate­2 risk, 
2546 (10%) patients in the derivation cohort as high risk, 
and 3090 (12%) patients in the derivation cohort as very­
high risk.
Over the derivation set, risk levels were associated with 
a monotonic independent increase in the HR for overall 
mortality (table 2, appendix p 5). This risk corresponded 
to unadjusted 2­year overall survival rates of 72·4% 
(95% CI 70·7–74·1; low risk), 64·1% (62·9–65·2; 
intermediate­1 risk), 57·6% (56·3–58·9; intermediate­2 
risk), 47·6% (45·4–49·8; high risk), and 36·2% 
(34·3–38·2; very high risk; figure 3A, appendix p 6). The 
increasing risk of transplantation failure was driven 
primarily by relapse (appendix pp 6–8).
An online interface for calculating the DRSS category 
and providing disease and disease status specific 
unadjusted overall survival curves (appendix pp 19–37) is 
available.
The distribution of the DRSS over the tuning and 
geographical validation cohorts was similar to the 
derivation cohort. In the tuning cohort, the low risk 
category consisted of 1653 (9%) of 18 365 total patients, 
the intermediate­1 risk category consisted of 7019 (38%) 
patients, the intermediate­2 risk category consisted of 
5655 (31%) patients, the high risk category consisted of 
1568 (9%) patients, and the very high risk category 
consisted of 2470 (13%) patients, compared with 
328 (10%; low risk), 1314 (39%; intermediate­1 risk), 
894 (27%; intermediate­2 risk), 342 (10%; high risk), and 
488 (14%; very high risk) of 3366 patients in the 
geographical validation cohort. Risk of death and relapse 
also followed the same pattern as in the derivation 
cohort, with DRSS being the strongest predictor of 
survival (figure 3B,C, table 2, appendix pp 5, 7–8). Over 
the tuning and geographical validation cohorts, the 
HRs for overall mortality of the intermediate­1 risk 
group were 1·25 (95% CI 1·14–1·37; p<0·0001) and 
1·48 (1·17–1·88, p=0·0011); intermediate­2 risk group 
(1·52 [1·38–1·67] and 1·62 [1·27–2·08]; p<0·0001); high 
risk group (2·04 [1·83–2·28] and 2·61 [2·01–3·39]; 
p<0·0001); and very high risk group (2·90 [2·62–3·22] 
and 3·70 [2·88–4·74]; p<0·0001). In a sensitivity analysis 
including in­vivo T cell depletion as a covariate in the 
Cox model (appendix p 9), the DRSS remained an 








N 25 534 18 365 3366
Age, years (median [IQR]) 53 (41–62) 51 (39–60) 52 (40–60)
Sex
Male 15 019 (58·8%) 10 842 (59·0%) 1911 (56·8%)
Female 10 459 (41·0%) 7488 (40·8%) 1453 (43·2%)
Unknown 56 (0·2%) 35 (0·2%) 2 (0·1%)
Karnofsky performance status
≥90 17 465 (68·4%) 13 139 (71·5%) 2585 (76·8%)
<90 6172 (24·2%) 4017 (21·9%) 741 (22·0%)
Unknown 1897 (7·4%) 1209 (6·6%) 40 (1·2%)
Diagnosis
Aggressive lymphoma† 1457 (5·7%) 1062 (5·8%) 211 (6·3%)
Acute lymphoblastic 
leukaemia‡
3474 (13·6%) 2699 (14·7%) 561 (16·7%)
Acute myeloid leukaemia 11 881 (46·5%) 8248 (44·9%) 1578 (46·9%)
Chronic lymphocytic leukaemia 564 (2·2%) 768 (4·2%) 54 (1·6%)
Hodgkin disease 741 (2·9%) 599 (3·3%) 189 (5·6%)
Indolent lymphoma§ 827 (3·2%) 751 (4·1%) 98 (2·9%)
Multiple myeloma 852 (3·3%) 783 (4·3%) 90 (2·7%)
Myelodysplastic syndrome 2977 (11·7%) 1700 (9·3%) 303 (9·0%)
Myeloproliferative neoplasms¶ 2761 (10·8%) 1755 (9·6%) 282 (8·4%)
Cell source
Bone marrow 2126 (8·3%) 2261 (12·3%) 1128 (33·5%)
Peripheral blood 22 943 (89·9%) 15 514 (84·5%) 2198 (65·3%)
Cord blood 465 (1·8%) 590 (3·2%) 40 (1·2%)
Donor
Matched related 8492 (33·3%) 6718 (36·6%) 979 (29·1%)
Haploidentical relative 1762 (6·9%) 989 (5·4%) 897 (26·6%)
Matched unrelated (10/10) 7689 (30·1%) 5679 (30·9%) 747 (22·2%)
Mismatched unrelated 
(<10/10)
2071 (8·1%) 1988 (10·8%) 446 (13·3%)
Unknown match unrelated 5055 (19·8%) 2401 (13·1%) 257 (7·6%)
Unrelated cord blood 465 (1·8%) 590 (3·2%) 40 (1·2%)
Sex-match
Not female-to-male 20 432 (80·0%) 14 359 (78·2%) 2577 (76·6%)
Female-to-male 4565 (17·9%) 3586 (19·5%) 707 (21·0%)
Unknown 537 (2·1%) 420 (2·3%) 82 (2·4%)
Cytomegalovirus serostatus pair
Donor – / recipient – 6777 (26·5%) 4408 (24·0%) 346 (10·3%)
Donor – / recipient + 5330 (20·9%) 4234 (23·1%) 843 (25·0%)
Donor + / recipient – 2098 (8·2%) 1537 (8·4%) 233 (6·9%)
Donor + / recipient + 10 289 (40·3%) 7421 (40·4%) 1782 (52·9%)
Unknown 1040 (4·1%) 765 (4·2%) 162 (4·8%)
Conditioning intensity
Myeloablative 12 476 (48·9%) 9964 (54·3%) 2494 (74·1%)
Reduced intensity 12 400 (48·6%) 8050 (43·8%) 856 (25·4%)
Unknown 658 (2·6%) 351 (1·9%) 16 (0·5%)
Data are n (%) unless otherwise indicated. *Italian centres. †Includes patients with B-cell non-Hodgkin lymphomas and 
patients with T-cell non-Hodgkin lymphomas. ‡Includes patients with biphenotypic acute leukaemia. These patients 
are separate from patients with advanced biphenotypic acute leukaemia who were excluded due to rarity. §Includes 
patients with mantle cell lymphoma. ¶Includes patients with myelodysplastic syndrome or myeloproliferative 
neoplasm overlap.
Table 1: The European Society for Blood and Marrow Transplantation population characteristics
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ALL, refractory 
B-NHL, aggressive, progressive disease or stable disease
Sec AML, adverse cytogenetics, refractory
AML, adverse cytogenetics, refractory 
AML, unknown cytogenetics, refractory 
B-NHL, aggressive, partial response 
AML, non-adverse cytogenetics, refractory 
Sec AML, unknown cytogenetics, refractory 
T-NHL, progressive disease or stable disease
MM, progressive disease or stable disease
MDS, EB, adverse cytogenetics
ALL, subsequent complete remission 
Mantle cell lymphoma, progressive disease or stable disease
AML, adverse cytogenetics or FLT3-ITD, subsequent complete remission 
Hodgkin lymphoma, progressive disease or stable disease
Sec AML, adverse cytogenetics, complete remission
CML, blast crisis 
Sec AML, non-adverse cytogenetics, refractory
MDS or MPN
AML, adverse cytogenetics, first complete remission 
MDS, adverse cytogenetics 
Mantle cell lymphoma, partial response 
B-NHL, indolent, partial response 
CLL, progressive disease or stable disease 
MDS, unknown cytogenetics
Sec AML, unknown cytogenetics, complete remission 
T-NHL, partial response 
AML, non-adv cytogenetics, unknown FLT3, subsequent complete remission
Myeloproliferative neoplasms
B-NHL, aggressive, complete remission
ALL, unknown Ph, first complete remission
T-NHL, complete remission 
AML, intermediate cytogenetics FLT3-ITD/NPM1WT first complete remission
Sec AML, non-adverse cytogenetics, complete remission 
B-NHL, indolent, complete remission
Mantle cell lymphoma, complete remission
AML, non (adv cytogenetics or FLT3-ITD), subsequent complete remission 
MDS, intermediate cytogenetics 
AML, unknown cytogenetics, first complete remission
ALL, Ph-, first complete remission 
Hodgkin lymphoma, partial response
CLL, partial response
Hodgkin lymphoma, complete remission
AML, intermediate cytogenetics, non (FLT3-ITD/NPM1WT), first complete remission
CML, chronic phase
ALL, Ph+, first complete remission
CLL, complete remission
AML, favourable cytogenetics, first complete remission
Disease or disease-status pair
HR (95% CI)







AML, intermediate cytogenetics, unknown FLT3, first complete remission
AML, unknown cytogenetics, subsequent complete remission
Biphenotypic AL, complete remission
CML, accelerated phase
MM, complete remission or very good partial response or partial response
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Figure 2: Disease-risk stratification system
The hazard ratios for overall survival of multiple diseases and disease-status combinations over the derivation set are plotted. Combinations were divided into five risk groups. adv=adverse 
cytogenetics. AL=acute leukaemia. ALL=acute lymphoblastic leukaemia. AML=acute myeloid leukaemia. B-NHL=B-cell non-Hodgkin lymphoma. CLL=chronic lymphocytic leukaemia. CML=chronic 
myelogenous leukaemia. EB=excess blasts. ITD=internal tandem duplication. MDS=myelodysplastic syndrome. MM=multiple myeloma. MPN=myeloproliferative neoplasm. Ph=Philadelphia 
chromosome. sec=secondary disease. T-NHL=T-cell non-Hodgkin lymphoma.
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We studied an independent cohort of 660 patients 
transplanted at MSKCC (appendix p 10). Most (361 [55%] 
of 660) of the patients in this cohort received peripheral 
blood CD34 selected allografts, all of whom received 
myeloablative conditioning.17 Acute myeloid leukaemia 
and myelodysplastic syndrome were the leading 
indications for transplantation, accounting for 207 (32%; 
acute myeloid leukaemia) and 115 (18%; myelodysplastic 
syndrome) of 660 patients. The median follow­up was 
5·7 years (IQR 4·5–7·1) and completeness of 2­year 
follow­up was 98·8%. In this smaller cohort, there was 
no survival segregation between groups that were low 
risk and intermediate­1 risk, meaning that these groups 
were therefore merged. The condensed DRSS scheme 
Derivation cohort Tuning cohort Geographic validation cohort
Cases/ events HR (95% CI) p value Cases/ events HR (95% CI) p value Cases/ events HR (95% CI) p value
Low risk 854/3298 1 (ref) ·· 538/1653 1 (ref) ·· 81/328 1 (ref) ··
Intermediate-1 
risk
2998/9528 1·26 (1·17–1·36) <0·0001 2697/7019 1·25 (1·14–1·37) <0·0001 485/1314 1·48 (1·17–1·88) 0·0011
Intermediate-2 
risk
2816/7072 1·53 (1·42–1·66) <0·0001 2608/5655 1·52 (1·38–1·67) <0·0001 379/894 1·62 (1·27–2·08) <0·0001
High risk 1195/2546 2·03 (1·86–2·22) <0·0001 859/1568 2·04 (1·83–2·28) <0·0001 190/342 2·61 (2·01–3·39) <0·0001
Very high risk 1746/3090 2·87 (2·63–3·13) <0·0001 1620/2470 2·90 (2·62–3·22) <0·0001 343/488 3·70 (2·88–4·74) <0·0001
HR=hazard ratio. *The full multivariable results for overall survival, relapse incidence and non-relapse mortality are presented in the appendix (pp 5, 7–8).
Table 2: HRs for overall mortality by disease-risk stratification system stratum*
Figure 3: Overall survival by the disease-risk stratification system (DRSS) and reclassification from the disease-risk index to the DRSS



























0 6 12 18 24 0 6 12 18 24
Time from transplantation (months) 
log-rank p<0·0001
347 (0) 306 (0) 270 (2) 242 (5) 225 (7)
·· ·· ·· ·· ··
193 (0) 161 (1) 128 (3) 110 (5) 102 (6)
52 (0) 44 (0) 32 (0) 26 (0) 21 (0)
0 6 12 18 240 6 12 18 24
68 (0) 47 (0) 36 (0) 27 (1) 23 (1)
Time from transplantation (months) 
328 (0) 286 (8) 263 (11) 239 (22) 206 (47)
1314 (0) 1103 (27) 980 (39) 851 (78) 749 (136)
894 (0) 700 (15) 597 (25) 533 (45) 464 (88)
342 (0) 252 (4) 197 (10) 169 (17) 144 (27)














1653 (0) 1339 (86) 1168 (132) 1058 (190) 975 (246)
7019 (0) 5322 (646) 4386 (925) 3655 (1354) 3238 (1569)
5655 (0) 3970 (548) 3214 (719) 2712 (947) 2430 (1081)
1568 (0) 1064 (123) 828 (167) 654 (218) 577 (241)
2470 (0) 1290 (217) 916 (299) 715 (352) 599 (391)
3298 (0) 2441 (467) 2097 (598) 1641 (962) 1311 (1230)
9528 (0) 6410 (1795) 5126 (2301) 3951 (3109) 3144 (3705)
7072 (0) 4761 (991) 3804 (1272) 2947 (1802) 2393 (2167)
2546 (0) 1611 (360) 1196 (448) 863 (645) 660 (777)
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C Internal validation—geographical D External validation
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separated patients into four distinct risk groups 
associated with increasing risk of mortality for 
intermediate­2 risk (HR 1·34 [95% CI 1·04–1·74], 
p=0·025), high risk (HR 2·03 [95% CI 1·39–2·95], 
p=0·00023) and very­high risk (HR 2·26 [95% CI 
1·62–3·15], p<0·0001) patients compared with the low 
risk and intermediate­1 risk group (appendix pp 11–12). 
The condensed scheme corresponded with 66·6% 
(95% CI 61·6–71·6; low risk and intermediate­1 
risk), 55·4% (48·3–62·5; intermediate­2 risk), 40·4% 
(27·0–53·7; high risk), and 34·8% (23·4–46·3; very high 
risk) 2­year overall survival (figure 3D). The DRSS 
remained an independent predictor of mortality after 
adjusting for ex­vivo CD34 + cell depletion in a sensitivity 
analysis (appendix p 13).
The DRI has a total of 44 categories versus 55 in the 
DRSS (appendix p 14). Including only patients who could 
be classified according to both systems, the AUC for 2­year 
overall survival with DRSS and DRI in the derivation 
cohort was 61·0 versus 58·9, 61·6 versus 59·27 in the 
tuning cohort, 63·3 versus 62·0 in the internal geographic 
cohort, and 61·6 versus 60·9 in the external cohort. In 
the derivation set, 709 (2·8%) of 25 534 patients were 
unclassifiable by the DRI but were captured in the DRSS. 
In the derivation cohort, the DRI classified 16 510 (65%) of 
25 534 patients as intermediate risk; 11 889 (65%) of 
18 365 patients as intermediate risk in the tuning cohort, 
2152 (64%) of 3366 patients as intermediate risk in the 
internal geographic validation cohort, and 426 (65%) of 
660 patients in the external geographic validation cohort. 
Corresponding estimates of 2­year overall survival were 
62·5% (95% CI: 61·6–63·3; derivation cohort), 61·5% 
(60·6–62·5; tuning cohort), and 64·8% (62·8–66·9; 
internal geographical validation and external­validation 
cohorts). The DRSS reclassified intermediate­risk DRI 
patients, with 855 (6%) low risk, 7111 (51%) intermediate­1 
risk, 5700 (41%) intermediate­2 risk, and 375 (3%) high 
risk or very high risk of 14 041 patients in a subanalysis 
combining the tuning and internal geographic validation 
cohorts (figure 4A). In the external­validation cohort 
268 (62%) were classified as low risk or intermediate­1 risk 
and 140 (35%) as intermediate 2 (appendix p 38) of 
440 intermediate DRI patients. Across cohorts, the 
reclassified DRSS tiers within the DRI intermediate­risk 
group were associated with distinct survival trajectories 
(figure 4B, appendix p 38). For instance, in the tuning and 
geographical validation cohort, patients categorised as 
intermediate­risk DRI had an estimated 2­year overall 
survival probability of 62·1% (95% CI 61·2–62·9); by 
DRSS, however, the same group was segregated into the 
five risk groups with 2­year overall survival of 73·1% 
(70·1–76·2; low risk), 64·4% (63·2–65·6; intermediate­1 
risk), 58·5% (57·1–59·9; intermediate­2 risk), 45·5% 
(38·7–52·4; high risk) and 45·7% (37·4–54·0; very high 
risk).
Discussion 
Overall survival following allogeneic HSCT is heavily 
dependent on the histological diagnosis and remission 
status at the time of transplantation.2,3 On the basis of 
these two features and additional molecular and cyto­
genetic data, we constructed the DRSS; a novel risk 
stratification system. The DRSS includes 15 diagnoses 
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Very high risk (DRSS)
A DRI and DRSS reclassification
B Intermediate-risk DRI patients stratified by DRSS
Figure 4: Reclassification of the DRI intermediate risk group by the DRSS
A mosaic plot comparing the distribution of risk assignments in the DRSS and revised DRI over the tuning and 
geographical validation cohorts (A). Column width represents the proportion of DRI categories. Column hight 
represent the proportion of DRSS categories. Most patients were categorised as intermediate risk by DRI and were 
further stratified by the DRSS. Overall survival in patients classified by the revised DRI as intermediate risk, in their 
respective DRSS risk categories (B). DRI=disease-risk index. DRSS=disease-risk stratification system.
Articles
www.thelancet.com/haematology   Vol 8   March 2021 e213
validated in two hold­out datasets; one internal from the 
EBMT and one external from a single­centre US cohort. 
Across all populations, the DRSS was the most important 
determinant of overall survival. Increasing risk of death 
with each level was primarily driven by relapse, suggesting 
that disease biology drives classification.
Acute myeloid leukaemia was the leading indication for 
allogeneic HSCT in this study.1 In the DRI,2,3 patients with 
acute myeloid leukaemia who had a complete remission 
were grouped without respect to complete remission 
order. De­novo and secondary acute myeloid leukaemia 
were considered as a single entity and FLT3­ITD and 
NPM1 mutation status were not included. Acute myeloid 
leukaemia categories have been refined in the DRSS. In 
agreement with Granfeldt Østgård and colleagues,12 
patients with de­novo acute myeloid leukaemia had 
improved overall survival when compared to patients with 
secondary acute myeloid leukaemia (appendix p 17). We 
did not account for secondary acute myeloid leukaemia 
causes (ie, therapy vs antecedent haematological disorder 
related), which might have further segregated patients.18 
Nevertheless, a distinction between de­novo and secondary 
acute myeloid leukaemia was informative and was 
therefore included. De­novo acute myeloid leukaemia was 
further sub­classified on the basis of the numerical order 
of remission; trans plantation in first complete remission 
was associated with better survival than in later complete 
remission. Notably, among patients with intermediate­
risk cyto genetics who were in either first complete 
remission or later complete remission, molecular markers 
had a major prognostic role. In first complete remission, 
FLT3­ITD+ and NPM1WT defined a distinct group with 
inferior survival, while any of the three remaining possible 
combinations of FLT3­ITD and NPM1 mutation statuses 
resulted in overlapping survival and were aggregated. The 
absence of separation between molecular subtypes might 
reflect selection bias as current guidelines suggest that 
acute myeloid leukaemia FLT3­ITD– and NPM1mut should 
be treated with con solidative chemo therapy.13 Latent 
covariates, such as initial induction failure and measurable 
residual disease (MRD), which are not captured in the 
registry, could result in an increased risk of recurrence 
and referral for trans plantation in first complete 
remission. In subsequent complete remission, the sample 
size did not allow exploration of the role of NPM1. 
FLT3­ITD status strongly stratified patients, to the extent 
that patients with FLT3­ITD acute myeloid leukaemia had 
poor outcomes similar to that observed with adverse­risk 
cytogenetics (appendix p 17). Therefore, we grouped them 
into one category. FLT3­ITD and NPM1 mutational status 
are central determinants of acute myeloid leukaemia 
thera peutic strategy.13 Their incorporation to transplan­
tation risk schemes has lagged since standardised 
reporting to registries has begun since the year 2016. 
Including these markers in the DRSS reflects a 
contemporary strategy to assess risk in patients with acute 
myeloid leukaemia undergoing allogeneic HSCT.
Prognostication in acute lymphoblastic leukaemia is a 
moving target as practice is evolving. Philadelphia­
positive acute lymphoblastic leukaemia, which did not 
have a distinct prognosis from Philadelphia­negative 
acute lymphoblastic leukaemia in the revised­DRI,2,3 was 
among the entities with the lowest risk for overall 
mortality in the DRSS. This improvement possibly 
reflects the routine clinical use of pre­transplantation 
and post­transplantation tyrosine­kinase inhibitors,19 
which was only partially captured in the registry. Risk 
estimation in acute lymphoblastic leukaemia will 
continue to change as more data for MRD and previous 
therapies accumulate.20 Progress in the care of other 
haematological malignancies will change the profile of 
patients coming into transplantation. Outcomes of trans­
plantation as an advanced treatment line could ultimately 
be worse than historical controls. In patients with 
aggressive B­cell non­Hodgkin lymphoma or T­cell non­
Hodgkin lymphoma, our findings suggest that achieving 
a complete remission before transplantation is imperative 
as patients who were not in a full remission were at high 
or very­high risk of mortality. Novel targeted therapies 
offer new hope in these populations.21,22 Overall, care in 
lymphoid malignancies is evolving. Therefore, adjust­
ment of transplantation indications and risk assessment 
will be required in the coming decade.
Risk grouping is inherently linked to loss of prognostic 
information.23 Acknowledging this limitation, risk 
categorisation is clinically useful and facilitates com­
parative studies across heterogeneous populations. On 
the derivation set, the large sample size allowed for 
stratification of patients into five risk groups, which was 
maintained in the tuning and geographical validation 
cohorts. The difference in risk between the low and 
intermediate­1 risk groups was small, albeit statistically 
significant. In the external validation cohort, the first 
two levels had an overlapping risk for overall mortality. 
The difference might have been related to the smaller 
sample size or major differences between the cohorts’ 
features, namely, the common application of CD34­
selected graft in the external cohort, as well as its absence 
of cord­blood or haploidentical transplants. Importantly, 
the prognostic utility of DRSS held after adjusting for 
T cell depletion in the internal and external validation 
cohorts (appendix pp 9, 13), suggesting that it is platform­
independent. Because transplantation studies are often 
restricted by sample size, as is the case in the external 
validation cohort, a four­level rather than five­level 
scheme, merging low risk and intermediate­1 risk 
groups, could be appropriate in such scenarios.
Prognostic classification is not fixed and should account 
for emerging data in future studies. The DRSS builds 
upon the scaffolds of the DRI,2,3 which has facilitated 
analyses of heterogeneous cohorts. However, at least 60% 
of patients in our cohort—and other cohorts3—fall under 
the intermediate risk group with DRI, limiting its utility.24 
The new scheme has more balanced grouping even when 
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considered as four, rather than five levels. Patients at the 
extremes could be candidates for strategies aimed at 
improving disease control (ie, patients who are high risk) 
or decreasing transplant toxicity (ie, patients who are low 
risk). The DRSS had a slightly higher AUC than the DRI. 
However, similar to the DRI, it aims to stratify risk rather 
than provide an individualised estimate of survival. 
Therefore, the AUC is not an optimal metric to evaluate 
both models. Overall, prognostic tools such as the DRI 
and DRSS provide an estimate of the relative risk and not 
outcome probabilities. Therefore, they should be used for 
risk stratification. To provide accurate probabilistic 
estimates of post­transplantation events, prediction 
models should be developed on disease­specific cohorts 
and include granular information regarding patient, 
disease, and treatment features.
Diagnosis and disease status are among the primary 
drivers of treatment success.1–4 As a result, it is a challenge 
to investigate allogeneic HSCT outcomes because studies 
often include cohorts with a wide range of indications.1,25–27 
To account for this heterogeneity, we propose the DRSS for 
estimating the risk of disease­associated mortality. The 
system was developed on one of the largest cohorts ever 
used in a transplantation study and was rigorously 
validated, showing its applicability in the widest range of 
settings. Nevertheless, the DRSS would benefit from 
independent validation in additional cohorts with differing 
practices, disease distribution, and transplant centre 
experience. Importantly, HSCT prognostication is con­
tinuously changing as care of haematological malig nancies 
improves.1 Therefore, the DRSS should be updated over 
time as new markers are introduced to registries. Future 
versions will optimally include a more comprehensive set 
of molecular and cytogenetic markers and MRD, which 
is currently not routinely captured in registries.20,28–30 A 
similarly constructed system for paediatric trans plantation 
would also be valuable and would necessitate the inclusion 
of non­malignant transplant indications. We see several 
applications for the DRSS. First, it can be used to facilitate 
interpretation and analysis of prospective and retrospective 
studies, including cohorts with mixed transplant 
indications. Second, DRSS can serve as a benchmark for 
trans plantation studies and informed consent discussions, 
as it was developed and tested in nearly 50 000 patients. We 
provide an interactive interface for clinicians and 
investigators to further explore our findings. Finally, the 
DRSS promotes the design of non­disease­specific trials 
(eg, conditioning regimens studies and graft­versus­host 
disease prophylaxis), opening the door to broader 
populations.
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